New Advances in Stem Cell Research
Ole Isacson, Harvard Medical School
Date: Thursday, April 3, 2008
Time: 12:00 PM - 1:15 PM
Location: Boisi Center, 24 Quincy Road
The past year has seen great leaps forward in stem cell research. New methods could allow scientists to create adaptable ("pluripotent") stem cells without destroying human embryos in the process. Could this scientific development eliminate the primary moral objection to stem cell research? Dr. Ole Isacson, a prominent Parkinson's Disease researcher, will join us to discuss his work with stem cells and the relationship between science and ethics.
Dr. Ole Isacson is Professor of Neurology (Neuroscience) at Harvard Medical School. He is the Director of the Center for Neuroregeneration Research/Neuroregeneration Laboratories at McLean Hospital and an NIH Udall Parkinson's Disease Research Center of Excellence grant awardee. Dr. Isacson is also a member of the Scientific Advisory Board of the Harvard NeuroDiscovery Center and Principal Faculty of Harvard Stem Cell Institute. He received his Medical Bachelor (1984) and Doctor of Medicine (a research doctoral degree in Medical Neurobiology, 1987) from the University of Lund in Sweden. Over the last decade his original laboratory has grown to an internationally recognized academic research center for Parkinson's disease and related disorders, funded by the NIH, DOD and private foundations. Dr. Isacson's scientific models and studies of conceptually new therapies for neurodegenerative diseases have resulted in many new findings and clinical trials for Parkinson's and Huntington's disease. He is Receiving Editor of the European Journal of Neuroscience and on the board of numerous scientific journals. He serves as a scientific reviewer and advisor to the NIH, DOD and many Parkinson community groups. Dr. Isacson has received several international prizes, research awards and lectureships. He is author or co-author of over 200 scientific research publications in neuroscience and neurology, and 3 books in his field.